Optimising treatment options for cancer patients NTRK gene fusion detection obtains breakthrough medical device identification

ArcherDX focuses on tackling bottlenecks in the second-generation sequencing of tumor mutation genesIts proprietary and powerful target gene sequencing platform uses proprietary chemical reagents to generate a highly enriched sequencing library to accurately detect gene fusion, point mutations, copy number variation (CNV) and RNA abundance from solid tumors, blood cancers, sarcoma and liquid biopsy samplesin addition, the company's partnership with Bayer is primarily aimed at expanding the accessibility of integrated testing for NTRK1, NTRK2, and NTRK3 gene fusion in patients to help improve treatment options for NTRK fusion cancer patients"cancers that carry the fusion of ntRK genes have long been difficult to detect." Our next-generation sequencing technology uses RNA to provide highly sensitive NTRK fusion detection without having to know any solid tumor fusion information in advance," said DrJason Myers, CEO and co-founder of ArcherDX"
" to help more patients benefit from Vitrakvi therapy, it is critical to develop next-generation sequencing kits," said Robert LaCaze, Head of Strategy, Oncology, Bayer OncologyReferences:ArcherDX Receives The SMetS Device Device To Detect NTRK Gene FusionsRetrieved 2020-05-19, from